(Q80273822)
Statements
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer (English)
J A Meyerhardt
K Stuart
C S Fuchs
A X Zhu
C C Earle
P Bhargava
L Blaszkowsky
P Enzinger
R J Mayer
C Lawrence